These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11715881)

  • 21. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Increasing number of dialysis-requiring patients with diabetic nephropathies. Better diabetes control and antihypertensive treatment can counteract the trend].
    Kurkus J; Schön S; Prütz KG; Torffvit O
    Lakartidningen; 2005 May 2-15; 102(18-19):1420-3. PubMed ID: 15929425
    [No Abstract]   [Full Text] [Related]  

  • 24. Losartan: lessons learned from the RENAAL study.
    Shahinfar S; Lyle PA; Zhang Z; Keane WF; Brenner BM
    Expert Opin Pharmacother; 2006 Apr; 7(5):623-30. PubMed ID: 16553578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
    Zhang Z; Shahinfar S; Keane WF; Ramjit D; Dickson TZ; Gleim GW; Mogensen CE; de Zeeuw D; Brenner BM; Snapinn SM
    J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetic nephropathy--prevention and treatment.
    Agarwal DK
    J Indian Med Assoc; 2002 Mar; 100(3):158-60, 162-3. PubMed ID: 12408275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-receptor blockade in renal disease: the hard issues.
    Sica DA
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107
    [No Abstract]   [Full Text] [Related]  

  • 30. Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
    Kimura G
    Clin Exp Nephrol; 2006 Sep; 10(3):226-7. PubMed ID: 17009082
    [No Abstract]   [Full Text] [Related]  

  • 31. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus.
    Postma MJ; de Zeeuw D
    Nephrol Dial Transplant; 2009 Oct; 24(10):2975-83. PubMed ID: 19605601
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The RENAAL Study. Effect of losartan on diabetic nephropathy].
    Kuhlmann MK; Köhler H
    Internist (Berl); 2002 May; 43(5):675-7. PubMed ID: 12085539
    [No Abstract]   [Full Text] [Related]  

  • 35. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
    J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
    Brenner BM; Cooper ME; de Zeeuw D; Grunfeld JP; Keane WF; Kurokawa K; McGill JB; Mitch WE; Parving HH; Remuzzi G; Ribeiro AB; Schluchter MD; Snavely D; Zhang Z; Simpson R; Ramjit D; Shahinfar S;
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):328-35. PubMed ID: 11967819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The NEPHRODIAB2 randomized trial].
    Villar E; Lièvre M; Labeeuw M; Pouteil-Noble C
    Nephrologie; 2003; 24(6):317-9. PubMed ID: 14584299
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
    Snyder RW; Berns JS
    Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
    [No Abstract]   [Full Text] [Related]  

  • 40. Microalbuminuria and mortality in type 2 diabetes.
    Strayer SM
    J Fam Pract; 1998 Aug; 47(2):89-90. PubMed ID: 9722786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.